---
title: "Louisiana v. FDA"
description: "The Supreme Court granted an emergency stay, preserving the status quo for mifepristone access via telehealth and pharmacy while litigation continues in the Fifth Circuit."
type: "case"
court: "U.S. Supreme Court (order)"
decided: "2026-05-14"
citation: "No. 23A___, 606 U.S. ___ (2026) (order granting stay)"
docket: "23A___"
status: "Order in force"
source_url: "https://www.abhortion.org/cases/louisiana-v-fda-2026.html"
---

# Louisiana v. FDA

_Full caption: Louisiana v. U.S. Food and Drug Administration_

**Citation:** No. 23A___, 606 U.S. ___ (2026) (order granting stay) · **Docket No.** 23A___

**Status:** Order in force

| Field | Value |
| --- | --- |
| Court | U.S. Supreme Court (order) |
| Decided | May 14, 2026 |
| Vote | Order granting emergency stay; no full opinion issued |
| Majority author | Per curiam order |

## Question presented

Whether a Fifth Circuit ruling that would have restricted telehealth and pharmacy access to mifepristone should be stayed pending further review, in a case brought by state intervenors after FDA v. Alliance for Hippocratic Medicine (2024) dismissed the physician plaintiffs for lack of standing.

## Holding

The Supreme Court granted an emergency stay, preserving the status quo for mifepristone access via telehealth and pharmacy while litigation continues in the Fifth Circuit.

## Reasoning

The order was procedural — the merits of the FDA's mifepristone REMS modifications were not decided. The case continues in the Fifth Circuit with three state intervenors (originally Missouri, Idaho, Kansas; later transferred).

## Opinions

### Majority — Per curiam order

_Not joined by any other justice_

The Supreme Court granted an emergency stay, preserving the status quo for mifepristone access via telehealth and pharmacy while litigation continues in the Fifth Circuit.

## Practical effect

Mail-order and pharmacy-dispensed mifepristone remain available nationwide pending litigation. The Trump administration has not sought to revoke FDA approval, though FDA Commissioner Marty Makary launched a 'safety review' in May 2025.

## Perspectives

The summaries below are descriptive, not evaluative — an attempt to represent fairly how each camp typically frames this case.

### Abolitionist framing

Abolitionists generally view the continued availability of mail-order abortion pills as the primary post-Dobbs loophole undermining state bans. Foundation to Abolish Abortion and similar groups argue the Comstock Act (18 U.S.C. §§ 1461–1462) already makes such mailings illegal and criticize the Trump administration for non-enforcement.

### Mainstream pro-life framing

Groups like AUL and SBA Pro-Life America press for FDA reversal or Comstock enforcement, arguing chemical abortion has become the new frontier requiring federal action.

### Pro-choice framing

Reproductive rights advocates hail the stay as preserving essential medication abortion access and criticize the underlying litigation as an attempt to impose a de facto national ban.

## Significance

The order itself is procedural, but the underlying dispute over mifepristone access is the most consequential unresolved federal abortion question post-Dobbs. Nearly two-thirds of U.S. abortions are now medication abortions.

| Measure | Score |
| --- | --- |
| Overall significance | 7 / 10 |
| Legal precedential weight | 3 |
| Practical impact on access | 8 |
| Movement relevance (abolitionist) | 7 |
| Enduring relevance, 2026 | 9 |

## Sources

### Primary sources

- [healthaffairs.org/content/forefront/s…](https://www.healthaffairs.org/content/forefront/supreme-court-temporarily-blocks-ruling-barring-telehealth-and-pharmacy-access)

### Secondary sources

- [cnbc.com/2025/11/25/abortion…](https://www.cnbc.com/2025/11/25/abortion-pill-mifepristone-access-trump-fda.html)

## Related cases

**Cites earlier cases:**

- [FDA v. Alliance for Hippocratic Medicine (2024)](fda-v-alliance-hippocratic-medicine-2024.md)

## Notes

Docket numbers and exact citations may update as the case develops. The stay was reported May 14, 2026 by the Center for Reproductive Rights and Health Affairs; verify current status before publication.